Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2023-008261 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Tri Minh Tran und 8 weiteren Autor:innen. Beteiligte Einrichtung: Lentigen Technology Inc., a Miltenyi Biotec Company, Gaithersburg, Maryland, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Pancreatic Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Chimeric antigen receptor (CAR) T-cell therapy target receptor tyrosine kinase-like orphan receptor 1 (ROR1) is broadly expressed in hematologic and solid tumors, however clinically-characterized ROR1-CAR T cells with single chain variable fragment (scFv)-R12 targeting domain failed to induce durable remissions, in part due to the immunosuppressive tumor microenvironment (TME). Herein, we describe the development of an improved ROR1-CAR with a novel, fully human scFv9 targeting domain, and augmented with TGFβRIIDN armor protective against a major TME factor, transforming growth factor beta (TGFβ).
Methods
CAR T cells were generated by lentiviral transduction of enriched CD4 + and CD8 + T cells, and the novel scFv9-based ROR1-CAR-1 was compared with the clinically-characterized ROR1-R12-scFv-based CAR-2 in vitro and in vivo.
Results
CAR-1 T cells exhibited greater CAR surface density than CAR-2 when normalized for %CAR + , and produced more interferon (IFN)-γ tumor necrosis factor (TNF)-α and interleukin (IL)-2 in response to hematologic (Jeko-1, RPMI-8226) and solid (OVCAR-3, Capan-2, NCI-H226) tumor cell lines in vitro. In vivo, CAR-1 and CAR-2 both cleared hematologic Jeko-1 lymphoma xenografts, however only CAR-1 fully rejected ovarian solid OVCAR-3 tumors, concordantly with greater expansion of CD8 + and CD4 + CAR T cells, and enrichment for central and effector memory phenotype. When equipped with TGFβ-protective armor TGFβRIIDN, CAR-1 T cells resisted TGFβ-mediated pSmad2/3 phosphorylation, as compared with CAR-1 alone. When co-cultured with ROR-1 + AsPC-1 pancreatic cancer line in the presence of TGFβ1, armored CAR-1 demonstrated improved recovery of killing function, IFN-γ, TNF-α and IL-2 secretion. In mouse AsPC-1 pancreatic tumor xenografts overexpressing TGFβ1, armored CAR-1, in contrast to CAR-1 alone, achieved complete tumor remissions, and yielded accelerated expansion of CAR + T cells, diminished circulating active TGFβ1, and no apparent toxicity or weight loss. Unexpectedly, in AsPC-1 xenografts without TGFβ overexpression, TGFβ1 production was specifically induced by ROR-1-CAR T cells interaction with ROR-1 positive tumor cells, and the TGFβRIIDN armor conferred accelerated tumor clearance.
Conclusions
The novel fully human TGFßRIIDN-armored ROR1-CAR-1 T cells are highly potent against ROR1-positive tumors, and withstand the inhibitory effects of TGFß in solid TME. Moreover, TGFβ1 induction represents a novel, CAR-induced checkpoint in the solid TME, which can be circumvented by co-expressing the TGβRIIDN armor on T cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lentigen Technology Inc., a Miltenyi Biotec Company, Gaithersburg, Maryland, USA.
- Lentigen Technology Inc., a Miltenyi Biotec Company, Gaithersburg, Maryland, USA dina.schneider@miltenyi.com.
ORCID-Profile: Dina Schneider
Zitieren
APA
Tran, T. M., Chand Thakuri, B. K., Nurmukhambetova, S., Lee, J. J., Hu, P., Tran, N. Q., Steimle, B., Dash, P., & Schneider, D. (2024). Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008261
Vancouver
Tran TM, Chand Thakuri BK, Nurmukhambetova S, Lee JJ, Hu P, Tran NQ, et al. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-008261
BibTeX
@article{Tran2024,
author = {Tran, Tri Minh and Chand Thakuri, Bal Krishna and Nurmukhambetova, Saule and Lee, Jia-Jye and Hu, Peirong and Tran, Ngoc Q and Steimle, Brittany and Dash, Pradyot and Schneider, Dina},
title = {Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2023-008261}
}
EUVIMED